Anthropic launches its own drug discovery activities by acquiring a one-employee biotech firm and advancing research on treatments for pediatric rare diseases

Key points

• •Anthropic announced on October 27 (local time) that it is advancing its own drug discovery activities targeting rare pediatric conditions such as muscular dystrophy.
• •The acquired company had one employee and had been conducting experiments with 11 external research institutions using the AI model Claude.
• •Anthropic stated that it is taking over the drug discovery research previously conducted by the acquired company.